Business Context and Reporting Period
Company: Teleflex Incorporated
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 27, 1998
Headquarters: Plymouth Meeting, Pennsylvania
Teleflex is a diversified manufacturer of precision mechanical and electrical controls, medical devices, and aerospace components. The company operates through three primary segments: Commercial (automotive, marine, industrial), Medical (hospital supplies, surgical devices), and Aerospace (cargo systems, turbine engine components). The company employs approximately 13,500 people and operates roughly 100 facilities globally.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and debt figures are not provided in the text of this filing. These figures are incorporated by reference from the 1998 Annual Report to Shareholders (pages 19-31 and 32-39).
- Market Capitalization: Approximately $1.25 billion (aggregate market value of voting stock held by non-affiliates as of February 1, 1999).
- Shares Outstanding: 37,623,388 Common Shares (as of February 1, 1999).
- Allowance for Doubtful Accounts: Ended the year at $4,577,000 (down from $5,668,000 in 1997).
- Backlog (Firm Orders as of Dec 27, 1998):
- Aerospace: $418 million (approx. 50% expected to be filled in 1999).
- Commercial: $124 million.
- Medical: $21 million.
Material Changes and Segment Performance
Revenue Mix (1998): Commercial (45%), Aerospace (31%), Medical (24%).
Backlog Trends:
- Aerospace: Increased from $364 million (1997) to $418 million (1998).
- Commercial: Increased from $98 million (1997) to $124 million (1998).
- Medical: Decreased from $26 million (1997) to $21 million (1998).
Strategic Acquisitions and Divestitures:
- Medical: Acquired Sterilization Management Group (SMG) in 1998 to expand instrument management services.
- Commercial: Sold the Truck Systems Division of United Parts in February 1998; retained the Driver Control Division to expand European automotive operations.
- Aerospace: Continued structural realignment by selling military/defense product lines in 1995-1996 to focus on commercial aerospace and turbine markets.
Outlook, Risks, and Management Commentary
Management Strategy: The company continues to invest in the "New Venture Fund," allocating 0.5% of sales to develop new products and services to reduce vulnerability to economic cycles. The focus remains on expanding into medical businesses and providing systems solutions in automotive and aerospace markets.
Risks and Contingencies:
- Environmental: The company is subject to various environmental laws and has been named a potentially responsible party at various sites by the EPA. Management does not expect these costs to be material to financial position or results of operations.
- Market Dependence: Sales are influenced by consumer spending patterns (Commercial), worldwide medical device spending (Medical), and aerospace industry spending (Aerospace).
- Competition: The company faces varying degrees of competition but relies on technical competence and engineering capabilities as its primary competitive advantage.
Guidance: The filing text does not provide specific numerical guidance for future periods. It notes that substantially all of the 1998 backlog for Medical and Commercial segments will be filled in 1999.
Investor Verification Checklist
- Verify consolidated revenue, net income, and cash flow figures in the 1998 Annual Report to Shareholders (incorporated by reference).
- Review the "Financial Review" section (pages 32-39 of the Annual Report) for detailed liquidity and market risk disclosures.
- Confirm the impact of the 1998 acquisition of SMG on the Medical segment's future profitability.
- Monitor the execution of the $418 million Aerospace backlog, noting that only half is expected to be recognized in 1999.
- Assess the integration of European automotive operations following the 1997-1998 acquisitions and divestitures.